Journal of Thoracic Oncology最新文献

{"title":"Erratum to 'Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review' [Journal of Thoracic Oncology Volume 19 Issue 7 (2024) 973-983].","authors":"Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo","doi":"10.1016/j.jtho.2025.06.026","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.06.026","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.","authors":"Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Christian Rolfo, Marco Tagliamento, Teodora Radonic, Kurt A Schalper, Vivek Subbiah, Umberto Malapelle, Anja C Roden, Rami Manochakian, Ming-Sound Tsao, Helena Linardou, Rina Hui, Silvia Novello, Alastair Greystoke, Anjali Saqi, Sylvie Lantuejoul, David M Hwang, Kelly Nevins, Murry Wynes, Saiama Waqar, Yuchen Han, Yasushi Yatabe, Wei-Chin Chang, Takuo Hayashi, Tae-Jung Kim, Paul Hofman, Fabio Tavora, Fred R Hirsch, Valeria Denninghoff, Natasha B Leighl, Alexander Drilon, Wendy A Cooper, Sanja Dacic, Pranshu Mohindra, Nick Pavlakis, Fernando Lopez-Rios","doi":"10.1016/j.jtho.2025.07.009","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.07.009","url":null,"abstract":"<p><strong>Context: </strong>Molecular Tumor Boards (MTBs) are multidisciplinary meetings of specialists dedicated to analyzing biomarker test results to provide personalized treatment recommendations. However, global disparities in the successful implementation of MTBs exist, driven by unequal access to molecular diagnostics and supportive multidimensional expertise.</p><p><strong>Objective: </strong>To establish recommendations for MTB implementation, outline practical frameworks for their operation, and address disparities in expertise and resources between new and established MTBs.</p><p><strong>Design: </strong>A modified Delphi method involved 37 international experts in three survey rounds and online meetings, with consensus defined as ≥75% agreement.</p><p><strong>Results: </strong>The panel identified a molecular biologist or pathologist with expertise in molecular diagnostics and tumor-specific medical oncologists as indispensable MTB members. Case selection should reflect institutional expertise and volume, with newer MTBs reviewing less selected cases to gain experience. Regular meetings are advised to avoid delays beyond 14 days from result availability to discussion. Reporting should be standardized to include clinicopathologic data (tumor characteristics, treatment history), biomarker findings (testing results, sample details), and recommendations (treatment, retesting, genetic counseling). Treatment options should be ranked by the level of evidence for actionability and may include options not available locally. Performance evaluation should consider changes in patient management based on MTB input and matched therapy rates.</p><p><strong>Conclusions: </strong>These MTB consensus recommendations are applicable across tumor types, despite being developed by lung cancer and molecular specialists and initiated by the International Association for the Study of Lung Cancer (IASLC). They provide a structured framework for MTB implementation, report standardization, case selection, and quality assessment, aiming to standardize practice and address gaps in expertise for personalized cancer care.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic.","authors":"Jarushka Naidoo, Abesh Niroula, Dipesh Uprety, Matthew Smeltzer, Nicole Geissen, Raymond U Osarogiagbon, Mari Mino-Kenudson, Yasushi Yatabe, Kristin Higgins, Aakash Desai, Karen L Reckamp, Jessica Jiyeong Lin, Stephen V Liu, Fiona Hegi-Johnson Franzcr, Nagashree Seetharamu, David Harpole, Martin J Edelman","doi":"10.1016/j.jtho.2025.06.028","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.06.028","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA.","authors":"Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira, Nicolas Girard, Yu Jung Kim, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Ki Hyeong Lee, Hailin Xiong, Soon Hin How, Ying Cheng, Gee-Chen Chang, James Chih-Hsin Yang, Benjamin Besse, Michael Thomas, Sujay Shah, Mahadi Baig, Joshua C Curtin, Jiarui Zhang, John Xie, Tao Sun, Seema Sethi, Miao Wang, Elizabeth Fennema, Mahesh Daksh, Mariah Ennis, Joshua M Bauml, Byoung Chul Cho","doi":"10.1016/j.jtho.2025.06.030","DOIUrl":"https://doi.org/10.1016/j.jtho.2025.06.030","url":null,"abstract":"<p><strong>Introduction: </strong>Lazertinib is a CNS-penetrant, third-generation epidermal growth factor (EGFR)-tyrosine kinase inhibitor (TKI) that was selected for combination with amivantamab due to its relatively low rates of wild-type EGFR toxicities. In the phase 3 MARIPOSA study, amivantamab plus lazertinib (amivantamab-lazertinib) significantly improved progression-free survival (PFS) and overall survival versus osimertinib in participants with treatment-naïve EGFR-mutant advanced non-small cell lung cancer. A lazertinib monotherapy arm was included to assess the contribution of components in the combination. This is the first randomized, double-blind comparison of 2 third-generation EGFR-TKIs, lazertinib and osimertinib.</p><p><strong>Methods: </strong>In MARIPOSA, 1074 participants were randomized 2:2:1 to receive amivantamab-lazertinib (n=429), osimertinib monotherapy (n=429), or lazertinib monotherapy (n=216). This exploratory analysis compared the efficacy and safety of lazertinib and osimertinib.</p><p><strong>Results: </strong>At a median follow-up of 22.0 months, median PFS was 18.5 months for lazertinib versus 16.6 months for osimertinib (HR, 0.98; 95% CI, 0.79-1.22; P=0.86). PFS results were comparable between arms among predefined subgroups. Among participants with measurable disease at baseline, objective response rate was 83% for lazertinib versus 85% for osimertinib, with a median duration of response among confirmed responders of 16.6 months versus 16.8 months, respectively. Median overall survival was not reached for both arms (HR, 1.00; 95% CI, 0.73-1.38) at the interim analysis. Adverse events for both arms were mostly grade 1-2 and frequently related to EGFR inhibition. Lazertinib was associated with lower rates of QT interval prolongation versus osimertinib.</p><p><strong>Conclusions: </strong>Lazertinib showed comparable efficacy and safety to osimertinib, including in predefined subgroups.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to the Letter to the Editor: “In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC”","authors":"Amanda Lindberg MSc,&nbsp;Patrick Micke MD, PhD,&nbsp;Carina Strell PhD","doi":"10.1016/j.jtho.2025.04.005","DOIUrl":"10.1016/j.jtho.2025.04.005","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e87-e89"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overdiagnosis of Lung Cancer From Low-Dose Computed Tomography Screening in Average-Risk Chinese Populations","authors":"Donghui Jin MD,&nbsp;Jiwei Wu MD,&nbsp;Wenqun Xing MD","doi":"10.1016/j.jtho.2025.03.050","DOIUrl":"10.1016/j.jtho.2025.03.050","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e89-e90"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Board of Directors","authors":"","doi":"10.1016/S1556-0864(25)00729-4","DOIUrl":"10.1016/S1556-0864(25)00729-4","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Page A3"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to ‘Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report’ [Journal of Thoracic Oncology Volume 20, Issue 5 (2025) 676-679]","authors":"Atsushi Yanagisawa MD,&nbsp;Takayuki Shiroyama MD, PhD,&nbsp;Kotaro Miyake MD, PhD,&nbsp;Yoshito Takeda MD, PhD,&nbsp;Atsushi Kumanogoh MD, PhD","doi":"10.1016/j.jtho.2025.04.015","DOIUrl":"10.1016/j.jtho.2025.04.015","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Page 983"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC","authors":"Qian Yan MD,&nbsp;Jinlin Liu MD, PhD","doi":"10.1016/j.jtho.2025.03.035","DOIUrl":"10.1016/j.jtho.2025.03.035","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e86-e87"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decision Trees and Random Forests: Nonlinear and Nonparametric Alternatives to Logistic Regression in Biological Data Analysis","authors":"Yoshiyasu Takefuji PhD","doi":"10.1016/j.jtho.2025.03.003","DOIUrl":"10.1016/j.jtho.2025.03.003","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 7","pages":"Pages e84-e85"},"PeriodicalIF":21.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}